Tecentriq Improves Survival Rates in Metastatic TNBC Patients Who Respond to Treatment, Phase 1 Clinical Trial Suggests
News
Women with metastatic triple-negative breast cancer (TNBC) who respond to the anti-PD-L1 immunotherapy Tecentriq (atezolizumab) live significantly longer than those who do not, according to data from a Phase 1 clinical ... Read more